Gliclazide API, produced by Soroush Mana Pharmed, is utilized as the key active component in the manufacture of oral gliclazide medication. Gliclazide belongs to the second generation of sulfonylurea drugs and stimulates pancreatic beta cells to increase insulin secretion. In addition to raising insulin levels, gliclazide also reduces hepatic gluconeogenesis, which can result in an increased number and sensitivity of insulin receptors and lower blood glucose levels. This medication effectively decreases fasting blood sugar, postprandial blood sugar, and glycated hemoglobin (HbA1c) levels.
Soroush Mana Pharmed is the first and only domestic producer of this pharmaceutical raw material in Iran. In 2023, total national consumption of this API was approximately 33 metric tons, and the company has successfully captured a significant share of the domestic market.
Repaglinide API, produced by Soroush Mana Pharmed, is utilized as the primary active component in the manufacture of oral repaglinide medication. Repaglinide is an antidiabetic agent from the meglitinide class, prescribed to control blood sugar levels in individuals with type 2 diabetes (non-insulin-dependent diabetes). This non-sulfonylurea hypoglycemic drug acts by inhibiting ATP-dependent potassium channels, depolarizing the cell membrane, and facilitating calcium influx through calcium channels.
By increasing intracellular calcium, repaglinide stimulates pancreatic beta cells to release more insulin.
Soroush Mana Pharmed is the first and only domestic manufacturer of this pharmaceutical ingredient at an industrial scale, and this product has been recognized as a knowledge-based product by the Vice-Presidency for Science and Technology
